Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flavio Vincenti

Showing results (81-90 of 119) with videos related to

Pageof 12
Sort By:
Transplantation|January 4, 2011
Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT studyAtul Humar, Ajit P Limaye, Emily A Blumberg, et al.
Transplantation|August 27, 2019
Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human PodocytesEfrat Harel, Jun Shoji, Vivek Abraham, et al.
Journal of the American Society of Nephrology : JASN|February 9, 2007
Active focal segmental glomerulosclerosis is associated with massive oxidation of plasma albuminLuca Musante, Giovanni Candiano, Andrea Petretto, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|July 24, 2012
Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II studyJosep Grinyo, Josefina Alberu, Fabiana L C Contieri, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 6, 2010
Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II studyLionel Rostaing, Pablo Massari, Valter Duro Garcia, et al.
BMJ Open|October 8, 2021
Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept studyOlivier Aubert, Gillian Divard, Julio Pascual, et al.
Clinical Transplantation|January 29, 2019
Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantationEfrat Harel, Jun Shoji, Vivek Abraham, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|June 15, 2006
Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipientsFlavio Vincenti, Amado de Andrés, Thomas Becker, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 11, 2018
A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donorFlavio Vincenti, Klemens Budde, Pierre Merville, et al.
Science Translational Medicine|March 20, 2020
A urine score for noninvasive accurate diagnosis and prediction of kidney transplant rejectionJoshua Y C Yang, Reuben D Sarwal, Tara K Sigdel, et al.
Pageof 12

Showing results (81-90 of 119) with videos related to

Sort By:
Pageof 12
Transplantation|January 4, 2011
Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT studyAtul Humar, Ajit P Limaye, Emily A Blumberg, et al.
Transplantation|August 27, 2019
Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human PodocytesEfrat Harel, Jun Shoji, Vivek Abraham, et al.
Journal of the American Society of Nephrology : JASN|February 9, 2007
Active focal segmental glomerulosclerosis is associated with massive oxidation of plasma albuminLuca Musante, Giovanni Candiano, Andrea Petretto, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|July 24, 2012
Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II studyJosep Grinyo, Josefina Alberu, Fabiana L C Contieri, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 6, 2010
Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II studyLionel Rostaing, Pablo Massari, Valter Duro Garcia, et al.
BMJ Open|October 8, 2021
Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept studyOlivier Aubert, Gillian Divard, Julio Pascual, et al.
Clinical Transplantation|January 29, 2019
Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantationEfrat Harel, Jun Shoji, Vivek Abraham, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|June 15, 2006
Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipientsFlavio Vincenti, Amado de Andrés, Thomas Becker, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 11, 2018
A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donorFlavio Vincenti, Klemens Budde, Pierre Merville, et al.
Science Translational Medicine|March 20, 2020
A urine score for noninvasive accurate diagnosis and prediction of kidney transplant rejectionJoshua Y C Yang, Reuben D Sarwal, Tara K Sigdel, et al.
Pageof 12